drugset / Trial / NCT04564833

Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery

NCT04564833

Phase 2 Completed 152 enrolled Renibus Therapeutics, Inc.
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the effect of RBT-1 (stannous protoporphyrin \[SnPP\]/iron sucrose \[FeS\]) on preconditioning response biomarkers in subjects who are at risk for AKI following cardiac surgery.

Timeline

Start
2021-08-04
Primary completion
2022-11-09
Completion
2023-02-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Iron sucrose Unknown 240 mg Intravenous
Subject stannic protoporfin Small molecule 45 mg Intravenous
Subject stannic protoporfin Small molecule 90 mg Intravenous

Indications